Home・Aktien・Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc

Open

BrancheGesundheitswesen

20.93 4.08

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.82

Max

21.03

Schlüsselkennzahlen
By Trading Economics
Einkommen	24M 30M
Verkäufe	13M 184M
KGV Branchendurchschnitt	12.309 57.002
EPS	0.8
Gewinnspanne	16.502
Angestellte	1,976
EBITDA	12M 45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+7.38% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	18M 864M
Vorheriger Eröffnungskurs	16.85
Vorheriger Schlusskurs	20.93

Nachrichtenstimmung

By Acuity

84%

16%

319 / 340 Ranking in Healthcare

Amphastar Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Amphastar Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

7.38% Vorteil

12-Monats-Prognose

Durchschnitt 21.67 USD 7.38%

Hoch 30 USD

Tief 20 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amphastar Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Amphastar Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

319 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.